EUVIMEDEUVIMED entdecken
Open Access

Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals

Maheen H Khan iD, Kristen R Ibanez iD, Courtney Bowen, Duncan Donohue iD, Ann Oluloro, Elizabeth M Swisher, Jung-Min Lee iD

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Maheen H Khan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Drug Approval, Genital Neoplasms, Female, Clinical Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate the impact of international enrollment in landmark gynecologic cancer (Gyn-Ca) trials that supported the US Food and Drug Administration (FDA) drug approvals. METHODS We examined the FDA drug approval database for approved Gyn-Ca agents between January 2014 and June 2024. We then extracted clinical trial identifiers supporting these approvals using FDA safety labels. Expected enrollment was calculated using gynecologic disease site incidence data from the US Cancer Statistics Program and compared with actual trial enrollment reported on ClinicalTrials.gov. RESULTS From 2014 to 2024, 30 Gyn-Ca trials supporting 28 FDA approvals were conducted in US/international (86.7%), international-only (10%), and US-only sites (3.3%) and enrolled 15,294 patients, with 14,053 remaining (74.0% White, 4.1% Black, 12.7% Asian, 8.7% other) after screening for trials not reporting race. Black (–11.0%; P < .0001), Hispanic/Latino (–3.5%; P < .0001), and elderly (–12.6%; P < .0001) participants were under-represented, whereas Asians (+6.8%; P < .0001) were over-represented. Asian (18.3% v 3.5% in trials with or without East Asian sites; odds ratio [OR], 6.19 [95% CI, 5.29 to 7.25]; P < .0001) and Hispanic/Latino (18.6% v 4.6% in trials with or without South American sites; OR, 4.75 [95% CI, 4.00 to 5.63]; P < .0001) enrollment was higher in trials that included East Asian and South American sites, respectively. Black enrollment did not improve despite trials including recruitment in Africa (3.2% v 4.1% Black enrollment in trials with or without African sites; OR, 0.83 [95% CI, 0.38 to 1.83]; P = .53). CONCLUSION Black, Hispanic/Latino, and elderly patients were under-represented in pivotal Gyn-Ca trials, whereas Asian patients were over-represented, compared with expected enrollment proportions. Postmarketing studies on under-represented groups should be considered to assess drug efficacy and safety in these populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalGenital Neoplasms, FemaleClinical Trials as TopicHumansFemaleUnited StatesUnited States Food and Drug AdministrationEthnicityMiddle AgedAgedAge FactorsRacial GroupsAdultPatient Selection

Autor:innen und Institutionen

  • Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Statistical Consulting and Scientific Programming Group, Computer and Statistical Services, Data Management Services, Inc (a BRMI company), NCI, Frederick, MD.
  • Department of Obstetrics & Gynecology, University of Washington, Seattle, WA.

ORCID-Profile: Maheen H Khan, Kristen R Ibanez, Duncan Donohue, Jung-Min Lee

Förderung

  • NCI NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Khan, M. H., Ibanez, K. R., Bowen, C., Donohue, D., Oluloro, A., Swisher, E. M., & Lee, J. M. (2025). Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals. JCO Global Oncology. https://doi.org/10.1200/go-24-00636

Vancouver

Khan MH, Ibanez KR, Bowen C, Donohue D, Oluloro A, Swisher EM, et al. Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals. JCO Global Oncology. 2025. doi:10.1200/go-24-00636

BibTeX
@article{Khan2025,
  author = {Khan, Maheen H and Ibanez, Kristen R and Bowen, Courtney and Donohue, Duncan and Oluloro, Ann and Swisher, Elizabeth M and Lee, Jung-Min},
  title = {Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00636}
}
Kostenlos starten →